Mark A. Lewis, MD

Scott Kopetz, MD, PhD, FACP, and Mark A. Lewis, MD, discuss how ctDNA assays have improved MRD detection in CRC.

Scott Kopetz, MD, PhD, FACP, and Mark A. Lewis, MD, discuss ongoing research in CRC utilizing ctDNA.

Scott Kopetz, MD, PhD, FACP, and Mark A. Lewis, MD, discuss how to approach conversations about ctDNA with patients with CRC.

Scott Kopetz, MD, PhD, FACP, and Mark A. Lewis, MD, discuss findings for ctDNA in stage II/III CRC from the BESPOKE CRC trial.

Scott Kopetz, MD, PhD, FACP, and Mark A. Lewis, MD, on data from the GALAXY arm of CIRCULATE-Japan for ctDNA in stage II to IV CRC.

Scott Kopetz, MD, PhD, FACP, and Mark A. Lewis, MD, on why ctDNA remains a focus of research in colorectal cancer.

The experts provide their final thoughts surrounding the impact of prospective trials and therapy regimens for treating patients with refractory mCRC.

Key opportunities to improve the mCRC treatment landscape are illustrated by the expert panelists.

Dr Kim offers key perspective for MSI-high patients based on data presented at ASCO 2024.

Multiple abstracts from ESMO 2023, including a focus on tumor location, are highlighted.

Data presented at ESMO 2023 and ASCO GI 2024 highlight the impact of prior therapy, including VEGF inhibitors or fluoropyrimidine, on mCRC treatment approach.

Key factors, particularly neuropathy, drive the discussion for platinum-based therapy for patients with non-refractory mCRC.

Considerations for patients to receive aggressive mCRC therapy regimens are navigated by the panelists.

Side effect profiles driven by fruquintinib use are discussed.

Drs Camidge and Lewis discuss how Dr Lewis’ MEN-1 diagnosis has affected his professional life and the importance of seeking patient perspectives.

Mark A Lewis, MD, and Scott Paulson, MD, share their experiences utilizing fruquintinib.

Richard Kim, MD, discusses the significance of real-world evidence when selecting treatment sequencing strategy.

Managing dose adjustments and tolerability in metastatic colorectal cancer (mCRC) treatment regimens for optimal efficacy is underscored.

Medical experts provide key takeaways and impacts from the FRESCO-2 study.

Marwan G Fakih, MD, drives a discussion highlighting a significant combination therapy in mCRC treatment.

Key safety considerations for the use of fruquintinib are explored.

Dr Parikh drives a conversation surrounding 3L treatment for patients diagnosed with metastatic colorectal cancer.

Medical experts open a discussion providing an update on the current impact of metastatic colorectal cancer and common treatment strategies.

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across hematologic oncology during the conference.